There is a body of thought that viruses such as the herpes simplex virus (HSV-1) is a contributing factor in the development of Alzheimer´s disease. In addition, Dr LaFerla at the University of California has suggested the activation of Lipoxin A4 (LXA4) could reduce the progress of (or delay the onset of) Alzheimer´s disease. This article provides the rationale for the use of mushroom nutrition (in the form of a combination of Coriolus versicolor and Hericium erinaceus (biomass)), to provide both anti-viral protection and activation of LXA4.
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Download PDF
Clinical articles
-
Mushroom Nutrition In Neurodegenerative Diseases
Prof. Vittorio Calabrese
Faculty of Medicine, University of Catania and University of Messina, Italy -
Targeting Neurogenesis with Mushroom Nutrition: A Mini Review
Dr. Elisabete Ferreiro, CNC-Center for Neuroscience and Cell Biology
CIBB-Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Prof. Tito Fernandes, CIISA
Faculty of Veterinary Medicine, Lisbon University, Lisbon, Portugal -
Central Nervous System Profiling of Hericium erinaceus Biomass Powder by an Electropharmacogram Using Spectral Field Power in Conscious Freely Moving Rats
Prof. Wilfried Dimpfel Justus
Liebig-University Giessen, Germany
Dr. Julie Wiebe
Nektium Pharm S.L., Las Palmas, Spain
Dr. Nigel Gericke, Gericke Consulting
Baden, Switzerland
-
A TCM Perspective on Mushroom Nutrition: Hericium erinaceus and Trametes versicolor (synn. Coriolus versicolor) as a synergistic combination
Karel Simonovsky and Zuzana Vancurikova